Research Analysts Offer Predictions for AbbVie Inc.’s FY2027 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBVFree Report) – Equities researchers at Leerink Partnrs upped their FY2027 earnings estimates for shares of AbbVie in a research note issued to investors on Monday, February 5th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $14.58 per share for the year, up from their previous estimate of $14.34. The consensus estimate for AbbVie’s current full-year earnings is $11.15 per share. Leerink Partnrs also issued estimates for AbbVie’s FY2028 earnings at $15.66 EPS.

Several other research analysts also recently weighed in on the stock. UBS Group cut their target price on shares of AbbVie from $157.00 to $150.00 and set a “neutral” rating for the company in a research note on Friday, October 20th. Morgan Stanley boosted their target price on shares of AbbVie from $193.00 to $196.00 and gave the company an “overweight” rating in a research note on Monday, October 30th. William Blair raised shares of AbbVie from a “market perform” rating to an “outperform” rating in a research note on Monday, January 29th. Barclays boosted their target price on shares of AbbVie from $175.00 to $185.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Raymond James boosted their target price on shares of AbbVie from $181.00 to $189.00 and gave the company an “outperform” rating in a research note on Monday. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $171.47.

Check Out Our Latest Report on AbbVie

AbbVie Price Performance

AbbVie stock opened at $175.02 on Tuesday. AbbVie has a 52 week low of $130.96 and a 52 week high of $175.56. The company has a quick ratio of 0.84, a current ratio of 0.96 and a debt-to-equity ratio of 4.59. The firm’s 50-day simple moving average is $158.60 and its 200 day simple moving average is $150.79. The firm has a market capitalization of $315.04 billion, a PE ratio of 64.11, a P/E/G ratio of 2.40 and a beta of 0.57.

AbbVie (NYSE:ABBVGet Free Report) last released its quarterly earnings data on Friday, February 2nd. The company reported $2.79 EPS for the quarter, topping the consensus estimate of $2.76 by $0.03. AbbVie had a net margin of 8.95% and a return on equity of 154.73%. The business had revenue of $14.30 billion for the quarter, compared to analyst estimates of $14.02 billion. During the same period in the previous year, the firm earned $3.60 EPS. The business’s revenue for the quarter was down 5.4% compared to the same quarter last year.

Hedge Funds Weigh In On AbbVie

Several institutional investors and hedge funds have recently made changes to their positions in the business. Miller Wealth Advisors LLC increased its position in AbbVie by 140.0% in the second quarter. Miller Wealth Advisors LLC now owns 240 shares of the company’s stock worth $32,000 after buying an additional 140 shares during the period. VitalStone Financial LLC increased its position in AbbVie by 218.4% in the second quarter. VitalStone Financial LLC now owns 242 shares of the company’s stock worth $33,000 after buying an additional 166 shares during the period. Hibernia Wealth Partners LLC acquired a new stake in AbbVie in the third quarter worth $36,000. PCA Investment Advisory Services Inc. acquired a new stake in AbbVie in the second quarter worth $38,000. Finally, True Wealth Design LLC acquired a new stake in AbbVie in the fourth quarter worth $39,000. 67.86% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 2,912 shares of the company’s stock in a transaction that occurred on Tuesday, December 26th. The stock was sold at an average price of $154.72, for a total value of $450,544.64. Following the completion of the transaction, the executive vice president now owns 55,903 shares in the company, valued at approximately $8,649,312.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.26% of the stock is owned by company insiders.

AbbVie Company Profile

(Get Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

See Also

Earnings History and Estimates for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.